PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study

PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study

Abstract Background Recaticimab (SHR-1209, a humanized monoclonal antibody against PCSK9) showed robust LDL-C reduction in healthy volunteers. This study aimed to further assess the efficacy and safety of recaticimab in patients with hypercholesterolemia. Methods In this randomized, double-blind, pl...

Full description

Bibliographic Details
Main Authors: Mingtong Xu, Xiaoxue Zhu, Junyan Wu, Yuling Zhang, Dong Zhao, Xuhong Wang, Yanhua Ding, Yu Cao, Chengqian Li, Wei Hu, Jianlong Sheng, Zhu Luo, Zeqi Zheng, Jinfang Hu, Jianying Liu, Xiaoyang Zhou, Aizong Shen, Xiaomei Ding, Yongdong Zhang, Yonggang Zhao, Yijing Li, Sheng Zhong, Shimin An, Jianjun Zou, Li Yan
Format: Article
Language:English
Published: BMC 2022-01-01
Series:BMC Medicine
Subjects:
PCSK9
Hypercholesterolemia
Recaticimab
Infrequent administration
Online Access:https://doi.org/10.1186/s12916-021-02208-w

Internet

https://doi.org/10.1186/s12916-021-02208-w

Similar Items